|
[1]
|
Gronberg H. Prostate cancer epidemiology[J]. Lancet, 2003, 361:859-64. doi: 10.1016/S0140-6736(03)12713-4 |
|
[2]
|
那彦群, 叶章群, 孙光, 等.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社, 2011:49-78. |
|
[3]
|
Gosselaar C, Roobol MJ, Roemeling S, et al. Screening for prostate cancer at low PSA range:the impact of digital rectal examination on tumor incidence and tumor characteristics[J]. Prostate, 2007, 67:154-161. doi: 10.1002/pros.20501 |
|
[4]
|
Philip J, Dutta Roy S, Ballal M, et al. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?[J]. BJU Int, 2005, 95:969-971. doi: 10.1111/j.1464-410X.2005.05449.x |
|
[5]
|
Vis AN, Boerma MO, Ciatto S, et al. Detection of prostate cancer:a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy[J]. Urology, 2000, 56:617-621. doi: 10.1016/S0090-4295(00)00681-6 |
|
[6]
|
Emiliozzi P, Corsetti A, Tassi B, et al. Best approach for prostate cancer detection:a prospective study on transperineal versus transrectal six-core prostate biopsy[J]. Urology, 2003, 61:961-966. doi: 10.1016/S0090-4295(02)02551-7 |
|
[7]
|
Furuno T, Demura T, Kaneta T, et al. Difference of cancer core distribution between first and repeat biopsy:in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy[J]. Prostate, 2004, 58:76-81. doi: 10.1002/pros.10298 |
|
[8]
|
Mai Z, Yan W, Zhou Y, et al. Transperineal template-guided prostate biopsy: 10 years of experience[J/OL]. BJU Int(2014-12-18). http://onlinelibrary.wiley.com/doi/10.1111/bju.13024/pdf. |
|
[9]
|
Yan W, Li H, Zhou Y, et al. Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11 region biopsy[J]. Urol Oncol, 2009, 27:520-524. doi: 10.1016/j.urolonc.2008.05.002 |
|
[10]
|
Oh WK. The evolving role of estrogen therapy in prostate cancer[J]. Clin Prostate Cancer, 2002, 1:81-89. doi: 10.3816/CGC.2002.n.009 |
|
[11]
|
Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer:2007 update[J]. J Urol, 2007, 177:2106-2131. doi: 10.1016/j.juro.2007.03.003 |
|
[12]
|
Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer[J]. Eur Urol, 2008, 53:68-80. doi: 10.1016/j.eururo.2007.09.002 |
|
[13]
|
de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer:results of a prospective randomized multicenter trial[J]. Clin Prostate Cancer, 2002, 1:163-171. doi: 10.3816/CGC.2002.n.018 |
|
[14]
|
Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer:data from Southwest Oncology Group Trial 9346(INT-0162)[J]. J Clin Oncol, 2006, 24:3984-3990. doi: 10.1200/JCO.2006.06.4246 |
|
[15]
|
Lane TM, Ansell W, Farrugia D, et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression[J]. Urol Int, 2004, 73:117-122. doi: 10.1159/000079690 |
|
[16]
|
Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer:is thehypothesis dead?[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17:2525-2530. doi: 10.1158/1055-9965.EPI-08-0448 |
|
[17]
|
Wirén S, Stocks T, Rinaldi S, et al. Androgens and prostate cancer risk:a prospective study[J]. Prostate, 2007, 67:1230-1237. doi: 10.1002/pros.20588 |
|
[18]
|
Lane BR, Stephenson AJ, Maji-Galluzzi C, et al. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy[J]. Urology, 2008, 72:1240-1245. doi: 10.1016/j.urology.2008.06.001 |
|
[19]
|
Isom Batz G, Bianco FJ Jr, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer[J]. J Urol, 2005, 173:1935-1937. doi: 10.1097/01.ju.0000158040.33531.e7 |
|
[20]
|
Zhang PL, Rosen S, Veeramachaneni R, et al. Association between prostate cancer and serum testosterone levels[J]. Prostate, 2002, 53:179-182. doi: 10.1002/pros.10140 |
|
[21]
|
Furuya Y, Nozaki T, Nagakawa O, et al. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer[J]. Endocr J, 2002, 49:85-90. doi: 10.1507/endocrj.49.85 |
|
[22]
|
Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy[J]. Eur Urol, 2007, 52:696-701. doi: 10.1016/j.eururo.2007.03.052 |
|
[23]
|
Walsh PC. Radical prostatectomy with preservation of sexual function impact on cancer control[J]. Prob Urol, 1987, 1:42. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b58fd029799dcb725465436dc7be4194 |
|
[24]
|
Marien TP, Lepor H. Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?[J]. BJU Int, 2008, 102:1581-1584. doi: 10.1111/j.1464-410X.2008.07921.x |
|
[25]
|
van der Poel HG, de Blok W, Joshi N, et al. Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy[J]. Eur Urol, 2009, 55:892-900. doi: 10.1016/j.eururo.2009.01.021 |
|
[26]
|
van der Poel HG, de Blok W. Role of extent of fascia preservation and erectile function after robot-assisted laparoscopic prostatectomy[J]. Urology, 2009, 73:816-821. doi: 10.1016/j.urology.2008.09.082 |
|
[27]
|
MA-AUA, Mid-Atlantic Section of the American Urological Association, 66th Annual Meeting, Cambridge, Maryland, USA, September 25-28, 2008. Abstracts[J]. Can J Urol, 2008, 15: 4200-4218. |
|
[28]
|
Yan W, Chen J, Zhou Y, et al. Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years[J]. Springerplus, 2014, 3:357. doi: 10.1186/2193-1801-3-357 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
